Anti-inflammatory activity of H1-receptor antagonists: Review of recent experimental research

Current Medical Research and Opinion

Volumn 20, Issue 1, 2004, Pages 73-81

  Gelfand, Erwin W ^a   Appajosyula, Sireesh ^b   Meeves, Suzanne ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b SANOFI   (France)

Author keywords

Anti allergic effects; Fexofenadine; H1 receptor antagonists; Histamine; IgE mediated inflammatory mechanisms

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIMYCIN; CAREBASTINE; CETIRIZINE; CYTOKINE; DESLORATADINE; EBASTINE; FEXOFENADINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LORATADINE; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIBLIOGRAPHIC DATABASE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG RESEARCH; HISTAMINE RELEASE; HUMAN; IN VITRO STUDY; INFLAMMATION; NEUROTOXICITY; RECEPTOR BLOCKING; REVIEW; SEDATION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTYROPHENONES; CELLS, CULTURED; HISTAMINE H1 ANTAGONISTS; LORATADINE; PIPERIDINES; TERFENADINE;

EID: 0347355153     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002586     Document Type: Review

References (38)

1. 1-receptor antagonists. Allergy 2000;55(Suppl 64):17-27
2. 1-receptor effects of antihistamines. Clin Exp Allergy 1999;29(Suppl 3):39-48
3. Meeves S, Joetham A, Gelfand EW. Fexofenadine exhibits antiallergic activity in vitro and vivo. J Allergy Clin Immunol 2001;107(Pt 2): Abstract 599
4. Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000;55(Suppl 64):34-9
5. Marshall GD Jr. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol 2000;106(Suppl):S303-9
6. Campbell A, Michel FB, Bremard-Oury C, et al. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996;52 (Suppl 1):15-19
7. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999;104:S132-7
8. American Academy of Allergy, Asthma, and Immunology. Allergic disorders: promoting best practices - the allergy report. Available at: http://theallergyreport.com/main.html. Accessed March 30, 2001
9. Wenzel SE. Investigational agents for the treatment of asthma. J Allergy Clin Immunol 1998;101:S421-3
10. 1 receptors. J Immunol 2001;166:4083-91
11. Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534-40
12. Casale TS, McCarthy RF. Future treatments in allergic disease. Medscape. Pulmonary Medicine Treatment Updates. June 8, 2000. Available at: http://www.medscape.com/Medscape/RespiratoryCare/TreatmentUpdate/2000/tu02/ pnt-tu02.html. Accessed December 6, 2001
13. Yamauchi K. Airway inflammatory marker. Nippon Rinsho 2001;59:1938-44
14. Sedgwick JB, Busse WW. Inhibitory effect of cetirizine on cytokine-enhanced in vitro eosinophil survival. Ann Allergy Asthma Immunol 1997;78:581-5
15. Schmi R, Walsh GM, Hartnell A, et al. Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro. Pediatr Allergy Immunol 1993;4:13-18
16. Kyan Aung U, Hallsworth M, Haskard D, et al. The effects of cetirizine on the adhesion of human eosinophils and neutrophils to cultured human umbilical vein endothelial cells. J Allergy Clin Immunol 1992;90:270-2
17. Leprevost C, Capron M, De Vos C, et al. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine). Int Arch Allergy Appl Immunol 1988;87:9-13
18. Jinquan T, Reimert CM, Deleuran B, et al. Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes. J Allergy Clin Immunol 1995;95(Suppl 5):979-86
19. Eda R, Sugiyama H, Hopp RJ, et al. Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993;71:373-8
20. Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 2000;55(Suppl 63):276
21. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101:410-20
22. Gelfand EW, Cui ZH, Takeda K, et al. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002;110:85-95
23. de Paulis A, Dente V, Onorati AM, et al. Fexofenadine inhibits the release of mediators and IL-4 from human FC, RI+ cells. Allergy 1999;54(Suppl 52):278
24. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-7
25. 1 receptor antagonist, on isolated human basophils [Abstr]. Inflamm Res 2000;49 (Suppl 1):S13-14
26. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31:1369-77
27. 1-antagonist descarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272-6
28. + cells. Clin Exp Allergy 1997;27:559-67
29. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-62
30. Marone G, Gentile M, Petraroli A, et al. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 2001;124:249-52
31. Marone G, Granata F, Spadaro G, et al. Antiinflammatory effects of oxatomide. J Invest Allergol Clin Immunol 1999;9:207-14
32. Hindmarch I, Shumsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive performance and subjective states. Neuropsychobiology 1994;29:97-104
33. 1-receptor antagonists. Clin Exp Allergy 1996;26:1092-107
34. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-21
35. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000;21:15-20
36. Hindmarch I, Shumsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side effects. Clin Exp Allergy 1999;29(Suppl 3):133-42
37. Zyrtec® prescribing information. Physicians' Desk Reference, 57th edn. Montvale, NJ: Medical Economics Co., 2003
38. Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Safety 2001;24:119-47